Request for Information on Input on Opportunities of Engagement of External Stakeholders With the “Illuminating the Druggable Genome” (IDG) Program, 18306-18307 [2017-07795]
Download as PDF
<![CDATA[
18306
Federal Register / Vol. 82, No. 73 / Tuesday, April 18, 2017 / Notices
Development, 31 Center Drive, Room 2A03,
MSC 2425, Bethesda, MD 20892, (301) 496–
0536, kaeserl@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Dated: April 12, 2017.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–07739 Filed 4–17–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
sradovich on DSK3GMQ082PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Genetic Basis and/or Omics Phenotypes of
Heart, Lung and Blood Disorders.
Date: May 12, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Residence Inn Bethesda, 7335
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Chang Sook Kim, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, 6701 Rockledge Drive, Room
7188, Bethesda, MD 20892–7924, 301–435–
0287, carolko@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
VerDate Sep<11>2014
16:55 Apr 17, 2017
Jkt 241001
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: April 12, 2017.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–07740 Filed 4–17–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; NIDDK Central
Biorepositories Non-renewable Sample
Access (X01) PAR–14–301.
Date: May 11, 2017.
Time: 1:00 p.m. to 2:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Najma Begum, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7349, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–8894,
begumn@niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; PAR–16–034:
NIDDK Ancillary Studies to Major Ongoing
Clinical Studies (R01).
Date: May 15, 2017.
Time: 2:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Najma Begum, Ph.D.,
Scientific Review Officer, Review Branch,
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
DEA, NIDDK, National Institutes of Health,
Room 7349, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–8894,
begumn@niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; NIDDK Diabetes
Research Centers (P30).
Date: May 24–25, 2017.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: DoubleTree by Hilton, Ballroom C,
8120 Wisconsin Avenue, Bethesda, MD
20814.
Contact Person: Najma Begum, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7349, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–8894,
begumm@niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: April 12, 2017.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–07736 Filed 4–17–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Request for Information on Input on
Opportunities of Engagement of
External Stakeholders With the
‘‘Illuminating the Druggable Genome’’
(IDG) Program
NIH seeks input from the
biomedical research community,
biotechnology and pharmaceutical
companies and other members of the
public on interest and opportunities of
engagement with the Illuminating the
Druggable Genome (IDG) Program. The
purpose of this Request for Information
(RFI) is to identify and obtain comments
on strategies for sharing potential data,
tools, and other resources of common
interest generated by the IDG Program
and by external stakeholders to
maximize the impact of the IDG
Program.
DATES: The IDG Program Request for
Information is open for public comment
for a period of 30 days. Comments must
be received by May 18, 2017 to ensure
consideration. After the public comment
period has closed, the comments
received by the IDG Program will be
considered in a timely manner by the
National Center for Advancing
SUMMARY:
E:\FR\FM\18APN1.SGM
18APN1
Federal Register / Vol. 82, No. 73 / Tuesday, April 18, 2017 / Notices
Translational Sciences (NCATS) and the
National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK).
Submissions may be sent
electronically to DK-IDG-Phase2-RFI@
mail.nih.gov or by mail to Dr. Karlie
Sharma, National Center for Advancing
Translational Sciences, National
Institutes of Health, 6701 Democracy
Blvd., Suite 900, Bethesda, MD 20892.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Questions about this request for
information should be directed to Dr.
Karlie Sharma, National Center for
Advancing Translational Sciences,
National Institutes of Health, 6701
Democracy Blvd., Suite 900, Bethesda,
MD 20892, DK-IDG-Phase2-RFI@
mail.nih.gov, 301–451–4965.
Out of the
nearly 30,000 genes in the human
genome, approximately 3,000 genes are
estimated to be part of the druggable
genome—the subset of genes expressing
proteins with the ability to bind druglike molecules. Yet, only about ten
percent of druggable proteins are
targeted by Food and Drug
Administration (FDA)-approved drugs.
Many proteins that comprise the
druggable genome are members of the Gprotein coupled receptor (GPCR), ion
channel, and kinase families. A
significant number of proteins within
these classes are understudied and are
the focus of the data and resource
generation initiative of the IDG Program.
SUPPLEMENTARY INFORMATION:
sradovich on DSK3GMQ082PROD with NOTICES
1. Goals and Requirements
The IDG Program was originally
funded as a three-year pilot program in
2014 with two overarching goals: (1)
Integrate information about
understudied druggable proteins from
disparate sources into a single
informatics site and (2) foster
technology development to enable the
determination of function and
therapeutic potential of understudied
druggable proteins. Having successfully
achieved these goals, the IDG Program is
currently transitioning to a new
implementation phase intended to:
• Expand the informatics tools
developed in the pilot phase to include
additional data and allow users to
access, analyze, and visualize a wide
range of information on sets of proteins.
• Facilitate the elucidation of the
function of understudied proteins from
the three key druggable protein families
(GPCR, ion channels, and kinases) by
generating new reagents and new data.
• Disseminate the IDG-generated
resources and data to the greater
scientific community.
VerDate Sep<11>2014
16:55 Apr 17, 2017
Jkt 241001
2. Information Requested
NIH is seeking input from national
and international experts and interested
members of the public that includes, but
is not limited to, the following areas:
• Resources that an outside
organization (biotechnology or
pharmaceutical company; non-profit
organization; academic institution and
national/international consortia) might
be willing to share with the IDG
Program and may:
Æ Strategize development of chemical
probes against proteins drawn from
the IDG focused list
Æ develop assays and platforms that can
help to answer questions about
understudied protein function
Æ identify reagents that may be useful
in annotation efforts
Æ provide data or knowledge on any
understudied protein
• Potential resources of the IDG
Program that are of interest to an outside
organization of the broader biomedical
research community including:
Æ Sharable databases of relevant subsets
of data on understudied proteins
Æ data analysis and query tools
Æ links between protein target and
disease pathologies
Æ new methods of analysis to accelerate
collection of data
This RFI is for planning purposes
only and should not be construed as a
solicitation for applications or
proposals, or as an obligation in any
way on the part of the United States
Federal government. The Federal
government will not pay for the
preparation of any information
submitted or for the government’s use.
Additionally, the government cannot
guarantee the confidentiality of the
information provided.
Dated: April 12, 2017.
Christopher P. Austin,
Director, NCATS.
Griffin P. Rodgers,
Director, NIDDK, Illuminating the Druggable
Genome Program, National Center for
Advancing Translational Sciences, National
Institute of Diabetes and Digestive and Kidney
Diseases.
[FR Doc. 2017–07795 Filed 4–17–17; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
18307
DEPARTMENT OF HEALTH AND
HUMAN SERVCES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Proposed Collection;
Comment Request
In compliance with Section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 concerning
opportunity for public comment on
proposed collections of information, the
Substance Abuse and Mental Health
Services Administration (SAMHSA)
will publish periodic summaries of
proposed projects. To request more
information on the proposed project or
to obtain a copy of the information
collection plans, call the SAMHSA
Reports Clearance Officer at (240) 276–
1243.
Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology.
Proposed Project: Strategic Prevention
Framework for Prescription Drugs
(SPF-Rx)—New
The Substance Abuse and Mental
Health Services Administration
(SAMHSA)’s Center for Substance
Abuse Prevention (CSAP) aims to
conduct a cross-site evaluation of the
Strategic Prevention Framework for
Prescription Drugs (SPF-Rx) program.
The SPF-Rx program is designed to
address nonmedical use of prescription
drugs (as well as opioid overdoses) by
raising awareness about the dangers of
sharing medications. and by working
with pharmaceutical and medical
communities. The SPF-Rx program aims
to promote collaboration between states/
tribes and pharmaceutical and medical
communities to understand the risks of
overprescribing to youth ages 12–17 and
adults 18 years of age and older. The
program also aims to enhance capacity
for, and access to, Prescription Drug
Monitoring Program (PDMP) data for
prevention purposes.
The SPF-Rx program aims to address
SAMHSA’s priorities on prevention and
E:\FR\FM\18APN1.SGM
18APN1
]]>Agencies
[Federal Register Volume 82, Number 73 (Tuesday, April 18, 2017)]
[Notices]
[Pages 18306-18307]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-07795]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Request for Information on Input on Opportunities of Engagement
of External Stakeholders With the ``Illuminating the Druggable Genome''
(IDG) Program
SUMMARY: NIH seeks input from the biomedical research community,
biotechnology and pharmaceutical companies and other members of the
public on interest and opportunities of engagement with the
Illuminating the Druggable Genome (IDG) Program. The purpose of this
Request for Information (RFI) is to identify and obtain comments on
strategies for sharing potential data, tools, and other resources of
common interest generated by the IDG Program and by external
stakeholders to maximize the impact of the IDG Program.
DATES: The IDG Program Request for Information is open for public
comment for a period of 30 days. Comments must be received by May 18,
2017 to ensure consideration. After the public comment period has
closed, the comments received by the IDG Program will be considered in
a timely manner by the National Center for Advancing
[[Page 18307]]
Translational Sciences (NCATS) and the National Institute of Diabetes
and Digestive and Kidney Diseases (NIDDK).
ADDRESSES: Submissions may be sent electronically to DK-IDG-Phase2-RFI@mail.nih.gov or by mail to Dr. Karlie Sharma, National Center for
Advancing Translational Sciences, National Institutes of Health, 6701
Democracy Blvd., Suite 900, Bethesda, MD 20892.
FOR FURTHER INFORMATION CONTACT: Questions about this request for
information should be directed to Dr. Karlie Sharma, National Center
for Advancing Translational Sciences, National Institutes of Health,
6701 Democracy Blvd., Suite 900, Bethesda, MD 20892, DK-IDG-Phase2-RFI@mail.nih.gov, 301-451-4965.
SUPPLEMENTARY INFORMATION: Out of the nearly 30,000 genes in the human
genome, approximately 3,000 genes are estimated to be part of the
druggable genome--the subset of genes expressing proteins with the
ability to bind drug-like molecules. Yet, only about ten percent of
druggable proteins are targeted by Food and Drug Administration (FDA)-
approved drugs. Many proteins that comprise the druggable genome are
members of the G-protein coupled receptor (GPCR), ion channel, and
kinase families. A significant number of proteins within these classes
are understudied and are the focus of the data and resource generation
initiative of the IDG Program.
1. Goals and Requirements
The IDG Program was originally funded as a three-year pilot program
in 2014 with two overarching goals: (1) Integrate information about
understudied druggable proteins from disparate sources into a single
informatics site and (2) foster technology development to enable the
determination of function and therapeutic potential of understudied
druggable proteins. Having successfully achieved these goals, the IDG
Program is currently transitioning to a new implementation phase
intended to:
Expand the informatics tools developed in the pilot phase
to include additional data and allow users to access, analyze, and
visualize a wide range of information on sets of proteins.
Facilitate the elucidation of the function of understudied
proteins from the three key druggable protein families (GPCR, ion
channels, and kinases) by generating new reagents and new data.
Disseminate the IDG-generated resources and data to the
greater scientific community.
2. Information Requested
NIH is seeking input from national and international experts and
interested members of the public that includes, but is not limited to,
the following areas:
Resources that an outside organization (biotechnology or
pharmaceutical company; non-profit organization; academic institution
and national/international consortia) might be willing to share with
the IDG Program and may:
[cir] Strategize development of chemical probes against proteins drawn
from the IDG focused list
[cir] develop assays and platforms that can help to answer questions
about understudied protein function
[cir] identify reagents that may be useful in annotation efforts
[cir] provide data or knowledge on any understudied protein
Potential resources of the IDG Program that are of
interest to an outside organization of the broader biomedical research
community including:
[cir] Sharable databases of relevant subsets of data on understudied
proteins
[cir] data analysis and query tools
[cir] links between protein target and disease pathologies
[cir] new methods of analysis to accelerate collection of data
This RFI is for planning purposes only and should not be construed
as a solicitation for applications or proposals, or as an obligation in
any way on the part of the United States Federal government. The
Federal government will not pay for the preparation of any information
submitted or for the government's use. Additionally, the government
cannot guarantee the confidentiality of the information provided.
Dated: April 12, 2017.
Christopher P. Austin,
Director, NCATS.
Griffin P. Rodgers,
Director, NIDDK, Illuminating the Druggable Genome Program, National
Center for Advancing Translational Sciences, National Institute of
Diabetes and Digestive and Kidney Diseases.
[FR Doc. 2017-07795 Filed 4-17-17; 8:45 am]
BILLING CODE 4140-01-P
